Clin Osteol 2007; 12(3): 118-120

Orally administered calcitonin - a new option in the osteoporosis and osteoarthritis treatment?News

S. Kutílek, T. Hála

Calcitonin is well known for its antiresorptive and analgetic effects. The application forms of calcitonin (nasal spray or subcutaneous injections) limit its wider use. Recent development of oral salmon calcitonin represents new therapeutic options in osteoporosis and osteoarthritis.

Keywords: oral calcitonin, osteoporosis, osteoarthritis

Published: December 11, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kutílek S, Hála T. Orally administered calcitonin - a new option in the osteoporosis and osteoarthritis treatment? Osteologický bulletin. 2007;12(3):118-120.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Srivastava AK, Libanati C, Hohmann O, Kriegman A, Baylink DJ Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover. Calcif Tissue Int. 2004 Dec;75:477-81. Epub 2004 Sep 16. Go to original source...
    2. Chesnut CH, Silverman S, Andriano K et al. A randomized trial of nasal spray sal­ mon calcitonin in postmenopausal women with estbalished osteoporosis. The Pre­ vent Recurrence Of Osteoporotic Fractures study. Am J Med 2000;109:267-76. Go to original source...
    3. Cranney A, Tuqwell P, Zytaruk N, Robinson V, Weaver B et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocrine Rev 2002;23:540-51. Go to original source...
    4. Munoz-Torres M, Alonso G, Raya MP. Calcitonin therapy in osteoporosis. Treat Endocrinol. 2004;3:117-32. Go to original source...
    5. Chesnut CH 3rd, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L. Effects of salmon cal­ citonin on trabecular microarchitecture as determined by magnetic resonance ima­ ging: results from the QUEST study. J Bone Miner Res. 2005 Sep;20:1548-61. Epub 2005 Apr 27. Go to original source...
    6. Stepan JJ, Zikán V.Calcitonin load test to assess the efficacy of salmon calcitonin. Clin Chim Acta. 2003;336:49-55. Go to original source...
    7. Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporosis Int 2002;13:858-67. Go to original source...
    8. Karsdal MA, Tanko LB, Riis BJ, Sondergard BC, Henriksen K, Altman RD, Cal­ citonin is involved in cartilage homeostasis: is calcitonin a treatment for OA? Osteoarthritis Cartilage 2006;14:617-24. Go to original source...
    9. Sondergaard BC, Wulf H, Henriksen K, Schaller S, Oestergaard S, Qvist P, Tankó LB, Bagger YZ, Christiansen C, Karsdal MACalcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage. 2006;14:759-68 Go to original source...
    10. Song KH, Chung SJ, Shim CK Enhanced intestinal absorption of salmon calcito­ nin (sCT) from proliposomes containing bile salts. J Control Release. 2005;106:298-308. Go to original source...
    11. Garcia-Fuentes M, Torres D, Alonso MJ. New surface-modified lipid nanopartic­ les as delivery vehicles for salmon calcitonin. Int J Pharm. 2005;296:122-32. Go to original source...
    12. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. A comparative study of the po­ tential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci 2005;25:133^3. Go to original source...
    13. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, Alonso MJ. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J Control Release. 2006;11:299-308. Go to original source...
    14. Prego C, Fabre M, Torres D, Alonso MJ. Efficacy and mechanism of action of chi­ tosan nanocapsules for oral peptide delivery. Pharm Res 2006;23:549-56. Go to original source...
    15. Sun P, Zhang X, Zang X, Zhou X, Chen Y, Arunakumara KK, Liang B. Anti-hypercalcemic effect of orally administered recombinant Saccharomyces cerevisiae expressing salmon calcitonin on hypercalcemic rats. Biotechnol Lett. 2007;29: 1013-8. Go to original source...
    16. Buclin T, Cosma Rochat M, Burckhardt P, Azria M, Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 2002;17:1478-85 Go to original source...
    17. Tanko LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004;19:1531-8. Go to original source...
    18. Phpaioannou NA, Triantafillopoulos IK, Khaldi L, Krallis N, Galanos A, Lyritis GP.Effect of calcitonin in early and late stages of experimentally induced osteo­ arthritis. A histomorphometric study. Osteoarthritis Cartilage 2007;15:386-95 Go to original source...
    19. Manicourt DH, Devogelaer JP, Azria M, Silverman S. Rationale for the potential use of calcitonin in osteoarthritis. J Musculoskelet Neuronal Interact. 2005;5: 285-93
    20. Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, Azria M, Christiansen C. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005;37:425-30 Go to original source...
    21. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers ofjoint metabolism in knee osteoarthritis. Arthri­ tis Rheum 2006;54:3205-11. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.